138 related articles for article (PubMed ID: 12429045)
1. Apolipoprotein E-deficient mice created by systemic administration of antisense oligodeoxynucleotides: a new model for lipoprotein metabolism studies.
Morishita R; Gibbons GH; Kaneda Y; Zhang L; Ogihara T; Dzau VJ
J Endocrinol; 2002 Nov; 175(2):475-85. PubMed ID: 12429045
[TBL] [Abstract][Full Text] [Related]
2. In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method.
Aoki M; Morishita R; Higaki J; Moriguchi A; Kida I; Hayashi S; Matsushita H; Kaneda Y; Ogihara T
Biochem Biophys Res Commun; 1997 Feb; 231(3):540-5. PubMed ID: 9070840
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice.
Shah PK; Nilsson J; Kaul S; Fishbein MC; Ageland H; Hamsten A; Johansson J; Karpe F; Cercek B
Circulation; 1998 Mar; 97(8):780-5. PubMed ID: 9498542
[TBL] [Abstract][Full Text] [Related]
4. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.
Morishita R; Gibbons GH; Ellison KE; Nakajima M; von der Leyen H; Zhang L; Kaneda Y; Ogihara T; Dzau VJ
J Clin Invest; 1994 Apr; 93(4):1458-64. PubMed ID: 8163650
[TBL] [Abstract][Full Text] [Related]
5. Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer.
Morishita R; Gibbons GH; Horiuchi M; Nakajima M; Ellison KE; Lee W; Kaneda Y; Ogihara T; Dzau VJ
J Cardiovasc Pharmacol Ther; 1997 Jul; 2(3):213-222. PubMed ID: 10684460
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation.
Boisvert WA; Spangenberg J; Curtiss LK
J Clin Invest; 1995 Aug; 96(2):1118-24. PubMed ID: 7635947
[TBL] [Abstract][Full Text] [Related]
7. Hypercholesterolemia induced by cholesterol- or cystine-enriched diets is characterized by different plasma lipoprotein and apolipoprotein concentrations in rats.
Sérougne C; Felgines C; Férézou J; Hajri T; Bertin C; Mazur A
J Nutr; 1995 Jan; 125(1):35-41. PubMed ID: 7815174
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery.
Morishita R; Gibbons GH; Kaneda Y; Ogihara T; Dzau VJ
Gene; 1994 Nov; 149(1):13-9. PubMed ID: 7958977
[TBL] [Abstract][Full Text] [Related]
9. Palm tocotrienols protect ApoE +/- mice from diet-induced atheroma formation.
Black TM; Wang P; Maeda N; Coleman RA
J Nutr; 2000 Oct; 130(10):2420-6. PubMed ID: 11015467
[TBL] [Abstract][Full Text] [Related]
10. Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes.
Tomita N; Morishita R; Yamamoto K; Higaki J; Dzau VJ; Ogihara T; Kaneda Y
J Gene Med; 2002; 4(5):527-35. PubMed ID: 12221646
[TBL] [Abstract][Full Text] [Related]
11. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet.
Purcell-Huynh DA; Farese RV; Johnson DF; Flynn LM; Pierotti V; Newland DL; Linton MF; Sanan DA; Young SG
J Clin Invest; 1995 May; 95(5):2246-57. PubMed ID: 7738190
[TBL] [Abstract][Full Text] [Related]
12. Supplementation of diets with the black rice pigment fraction attenuates atherosclerotic plaque formation in apolipoprotein e deficient mice.
Xia M; Ling WH; Ma J; Kitts DD; Zawistowski J
J Nutr; 2003 Mar; 133(3):744-51. PubMed ID: 12612147
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.
Véniant MM; Pierotti V; Newland D; Cham CM; Sanan DA; Walzem RL; Young SG
J Clin Invest; 1997 Jul; 100(1):180-8. PubMed ID: 9202070
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.
Pászty C; Maeda N; Verstuyft J; Rubin EM
J Clin Invest; 1994 Aug; 94(2):899-903. PubMed ID: 8040345
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice.
Zhang W; Yancey PG; Su YR; Babaev VR; Zhang Y; Fazio S; Linton MF
Circulation; 2003 Nov; 108(18):2258-63. PubMed ID: 14581413
[TBL] [Abstract][Full Text] [Related]
16. Quantification and immunolocalization of apolipoprotein E in experimental atherosclerosis.
Badimon JJ; Kottke BA; Chen TC; Chan L; Mao SJ
Atherosclerosis; 1986 Jul; 61(1):57-66. PubMed ID: 3730054
[TBL] [Abstract][Full Text] [Related]
17. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice.
van Ree JH; van den Broek WJ; Dahlmans VE; Groot PH; Vidgeon-Hart M; Frants RR; Wieringa B; Havekes LM; Hofker MH
Atherosclerosis; 1994 Nov; 111(1):25-37. PubMed ID: 7840811
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.
Kawauchi M; Suzuki J; Morishita R; Wada Y; Izawa A; Tomita N; Amano J; Kaneda Y; Ogihara T; Takamoto S; Isobe M
Circ Res; 2000 Nov; 87(11):1063-8. PubMed ID: 11090553
[TBL] [Abstract][Full Text] [Related]
19. Efficient introduction of macromolecules and oligonucleotides into brain capillary endothelial cells using HVJ-liposomes.
Matsuo H; Okamura T; Chen J; Takanaga H; Ohtani H; Kaneda Y; Naito M; Tsuruo T; Sawada Y
J Drug Target; 2000; 8(4):207-16. PubMed ID: 11144231
[TBL] [Abstract][Full Text] [Related]
20. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
Véniant MM; Sullivan MA; Kim SK; Ambroziak P; Chu A; Wilson MD; Hellerstein MK; Rudel LL; Walzem RL; Young SG
J Clin Invest; 2000 Dec; 106(12):1501-10. PubMed ID: 11120757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
